Skip to main content
    B

    Bright Minds Biosciences Inc (DRUG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.51
    -2.10 (-9.29%)

    Market Cap: $227.96M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Bright Minds Biosciences Inc (DRUG) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Bright Minds Biosciences (DRUG) has a market cap of $227.96M. Its share count is up 38.77% from a year earlier.

    Total Valuation

    Market Cap$227.96M
    Latest price (Nov 17, 2026)$20.51

    Key Dates

    The next earnings report is expected on Dec 22, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateDec 22, 2026 (expected)
    Last Earnings DateAug 14, 2026
    Fiscal Year EndSeptember

    Share Statistics

    The share count rose 2.51% in the quarter ended Jun 30, 2026 and grew 45.41% a year over 2 years.

    Shares Outstanding9.83M
    Shares Change (YoY)+38.77%
    Shares Change (QoQ)+2.51%
    Share Count Growth (2Y CAGR)+45.41%

    Price Statistics

    The stock is down 64.57% over 52 weeks and trades 56.49% below its 50-day average.

    Beta (1Y)1.41
    52-Week Change-64.57%
    1-Month Change-61.89%
    3-Month Change-75.80%
    6-Month Change-72.48%
    5-Year Change+54.44%
    Total Return (1Y)-64.57%
    Total Return (3Y CAGR)+152.97%
    Total Return (5Y CAGR)-4.08%
    Return vs SPY (1Y)-76.03%
    Max Drawdown (1Y)-80.25%
    Max Drawdown (3Y)-80.25%
    Sharpe Ratio (1Y)-1.03
    Correlation with SPY (1Y)0.19
    50-Day Average$47.14
    200-Day Average$69.54
    52-Week Range$17.40 to $123.75
    RSI (14 Days)26.5
    Average Volume (20 Days)291.39K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 121.97x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio121.97x
    Quick Ratio121.97x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -11.21% over the last 12 months, against a 5-year average of -69.39%.

    Return on Equity (ROE)-8.21%
    Return on Assets (ROA)-8.14%
    Return on Invested Capital (ROIC)-11.21%
    ROE (5Y Average)-72.62%
    ROA (5Y Average)-66.77%
    ROIC (5Y Average)-69.39%

    Scores

    DRUG has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was CAD 0 over the last 12 months.

    RevenueCAD 0
    Gross ProfitCAD -72.09K
    Operating IncomeCAD -39.87M
    Pretax IncomeCAD -24.75M
    Net IncomeCAD -24.75M

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 99.18% of the CAD 310.84M in total assets.

    Working CapitalCAD 308.24M
    Shareholder EquityCAD 308.30M
    Total AssetsCAD 310.84M
    Total LiabilitiesCAD 2.55M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Stock Splits

    The last split was a 1-for-5 reverse split on Jul 14, 2023.

    Last Split DateJul 14, 2023
    Split TypeReverse split
    Split Ratio1:5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About DRUG

    What is DRUG's market cap?

    Bright Minds Biosciences has a market cap of $227.96M.

    How many shares of DRUG are outstanding?

    Bright Minds Biosciences has 9.83M shares outstanding. The count is up 38.77% from a year earlier.

    Does DRUG pay a dividend?

    No. Bright Minds Biosciences does not pay a dividend.